EUVIMEDEUVIMED entdecken
Crossref

Infections following chimeric antigen receptor T cell therapy: 2018–2022

Vishakh C Keri iD, Lea M Monday, Jahanavi M Ramakrishna, Rahul Vyas, Abhinav Deol, Mahmoud Al-Saadi, Pranatharthi H Chandrasekar

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Vishakh C Keri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious diseases, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T‐cell therapy is an emerging therapeutic modality for relapsed and refractory hematological malignancies. Infectious complications following CAR T‐cell therapy are not well defined.

Methods

This is a retrospective analysis of data on patients who received CAR T‐cell therapy between April 2018 and December 2022 at the Karmanos Cancer Center, Detroit. Patients’ data were collected up to their last known clinic or inpatient follow‐up visit. An infectious episode was defined as any microbiologically proven or clinically documented infection.

Results

Seventy‐six patients received therapy with FDA‐approved CAR T‐cell products. Thirty‐three patients (43.4%) had at least one infectious episode. There were 61 infectious episodes during a median follow‐up of 184 (96–340) days. Median duration for the onset of infection was 59 (22–209) days. Bacterial and viral infections occurred in 42.6% and 41% of the infectious episodes, respectively. COVID‐19 was the most common infectious complication (14.8%). Time‐to‐event analysis showed that most infections occurred within the first 100 days. Empirical antibiotic use during Cytokine Release Syndrome/Immune effector Cell‐Associated Neurotoxicity Syndrome (CRS/ICANS) in the absence of documented bacterial infection was reported in 85.7% of patients. Clostridioides difficile accounted for 11.5% of all infectious episodes. Five of six patients with C. difficile infection had CRS/ICANS and received antibiotics.

Conclusion

COVID‐19 and C. difficile infection were the most common infections following CAR T‐cell therapy. Most infections occurred within the first 100 days. Empiric antibiotic use and C. difficile infection were common in patients with CRS/ICANS, in the absence of documented bacterial infection, thus providing an excellent opportunity for antimicrobial stewardship in this population. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenCOVID-19HumansMaleRetrospective StudiesFemaleMiddle AgedAdultAgedBacterial InfectionsHematologic NeoplasmsVirus DiseasesYoung AdultAnti-Bacterial AgentsSARS-CoV-2Cytokine Release Syndrome

Stichwörter der Autor:innen

CAR T‐cell therapyClostridioides difficileinfections

Substanzen

Receptors, Chimeric AntigenAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious diseases, Wayne State University, Detroit, Michigan, USA.
  • Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA.
  • Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
  • Division of Infectious diseases, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.

ORCID-Profile: Vishakh C Keri

Zitieren

APA

Keri, V. C., Monday, L. M., Ramakrishna, J. M., Vyas, R., Deol, A., Al-Saadi, M., & Chandrasekar, P. H. (2024). Infections following chimeric antigen receptor T cell therapy: 2018–2022. Transplant Infectious Disease. https://doi.org/10.1111/tid.14376

Vancouver

Keri VC, Monday LM, Ramakrishna JM, Vyas R, Deol A, Al-Saadi M, et al. Infections following chimeric antigen receptor T cell therapy: 2018–2022. Transplant Infectious Disease. 2024. doi:10.1111/tid.14376

BibTeX
@article{Keri2024,
  author = {Keri, Vishakh C and Monday, Lea M and Ramakrishna, Jahanavi M and Vyas, Rahul and Deol, Abhinav and Al-Saadi, Mahmoud and Chandrasekar, Pranatharthi H},
  title = {Infections following chimeric antigen receptor T cell therapy: 2018–2022},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14376}
}
Kostenlos starten →